File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Long-term follow-up of patients receiving salvage chemotherapy for intermediate and high grade non-Hodgkin's lymphomas

TitleLong-term follow-up of patients receiving salvage chemotherapy for intermediate and high grade non-Hodgkin's lymphomas
Authors
Issue Date1990
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 1990, v. 8 n. 3, p. 133-140 How to Cite?
AbstractThis is an analysis of the long-term follow-up data of 99 patients receiving HOAP-Bleo, IMVP-16 and PAC as salvage chemotherapy for refractory or relapsed intermediate or high grade non-Hodgkin's lymphomas. Most of the patients received HOAP-Bleo or PAC following failure of initial chemotherapy and IMVP-16 was used mainly for HOAP-Bleo failures. The longest follow-up time of the surviving patients was 108 months. Twenty-two and 29 per cent of the patients survived beyond 2 years following HOAP-Bleo and PAC respectively. The treatment outcome following IMVP-16 was worst with a 2-year survival of only 5 per cent, as it was used mainly following HOAP-Bleo failures. Although the prognosis of these refractory or relapsed cases are poor, salvage treatment is still worthwhile as a small proportion of these patients may have long-lasting remissions and occasional patients may be cured. Newer approaches such as autologous bone marrow transplantation should be compared with current salvage chemotherapy regimens.
Persistent Identifierhttp://hdl.handle.net/10722/161817
ISSN
2015 Impact Factor: 3.494
2015 SCImago Journal Rankings: 0.767

 

DC FieldValueLanguage
dc.contributor.authorLiang, RHSen_US
dc.contributor.authorChiu, EKWen_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorTodd, Den_US
dc.contributor.authorNg, RPen_US
dc.contributor.authorHo, FFen_US
dc.contributor.authorLoke, SLen_US
dc.date.accessioned2012-09-05T05:15:16Z-
dc.date.available2012-09-05T05:15:16Z-
dc.date.issued1990en_US
dc.identifier.citationHematological Oncology, 1990, v. 8 n. 3, p. 133-140en_US
dc.identifier.issn0278-0232en_US
dc.identifier.urihttp://hdl.handle.net/10722/161817-
dc.description.abstractThis is an analysis of the long-term follow-up data of 99 patients receiving HOAP-Bleo, IMVP-16 and PAC as salvage chemotherapy for refractory or relapsed intermediate or high grade non-Hodgkin's lymphomas. Most of the patients received HOAP-Bleo or PAC following failure of initial chemotherapy and IMVP-16 was used mainly for HOAP-Bleo failures. The longest follow-up time of the surviving patients was 108 months. Twenty-two and 29 per cent of the patients survived beyond 2 years following HOAP-Bleo and PAC respectively. The treatment outcome following IMVP-16 was worst with a 2-year survival of only 5 per cent, as it was used mainly following HOAP-Bleo failures. Although the prognosis of these refractory or relapsed cases are poor, salvage treatment is still worthwhile as a small proportion of these patients may have long-lasting remissions and occasional patients may be cured. Newer approaches such as autologous bone marrow transplantation should be compared with current salvage chemotherapy regimens.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_US
dc.relation.ispartofHematological Oncologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subject.meshBleomycin - Administration & Dosageen_US
dc.subject.meshCisplatin - Administration & Dosageen_US
dc.subject.meshCyclophosphamide - Administration & Dosageen_US
dc.subject.meshCytarabine - Administration & Dosageen_US
dc.subject.meshDoxorubicin - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHarringtonines - Administration & Dosageen_US
dc.subject.meshHumansen_US
dc.subject.meshIfosfamide - Administration & Dosageen_US
dc.subject.meshLymphoma, Non-Hodgkin - Drug Therapy - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMesna - Administration & Dosageen_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshPrednisone - Administration & Dosageen_US
dc.subject.meshVincristine - Administration & Dosageen_US
dc.titleLong-term follow-up of patients receiving salvage chemotherapy for intermediate and high grade non-Hodgkin's lymphomasen_US
dc.typeArticleen_US
dc.identifier.emailLiang, RHS:rliang@hku.hken_US
dc.identifier.authorityLiang, RHS=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/hon.2900080304en_US
dc.identifier.pmid1695607-
dc.identifier.scopuseid_2-s2.0-0025004161en_US
dc.identifier.volume8en_US
dc.identifier.issue3en_US
dc.identifier.spage133en_US
dc.identifier.epage140en_US
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLiang, RHS=26643224900en_US
dc.identifier.scopusauthoridChiu, EKW=24827833600en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US
dc.identifier.scopusauthoridNg, RP=7102153823en_US
dc.identifier.scopusauthoridHo, FF=7103408190en_US
dc.identifier.scopusauthoridLoke, SL=7006559512en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats